ABUS vs. LYEL, APLS, OGN, HCM, IBRX, AMRX, XENE, MIRM, ARWR, and AAPG
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Lyell Immunopharma (LYEL), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
Arbutus Biopharma vs.
Lyell Immunopharma (NASDAQ:LYEL) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Arbutus Biopharma has higher revenue and earnings than Lyell Immunopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lyell Immunopharma had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 7 mentions for Lyell Immunopharma and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.78 beat Lyell Immunopharma's score of 0.44 indicating that Arbutus Biopharma is being referred to more favorably in the news media.
Lyell Immunopharma has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.
Arbutus Biopharma has a net margin of -1,137.65% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Arbutus Biopharma's return on equity.
66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by insiders. Comparatively, 20.3% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Lyell Immunopharma presently has a consensus price target of $20.00, indicating a potential upside of 93.05%. Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 54.28%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Arbutus Biopharma.
Arbutus Biopharma received 422 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 70.66% of users gave Arbutus Biopharma an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote.
Summary
Arbutus Biopharma beats Lyell Immunopharma on 11 of the 18 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ABUS) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy ABUS Stock Free ABUS Stock Alerts